Literature DB >> 20207492

Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.

Seok Hyun Son1, Byung Ock Choi, Mi Ryeong Ryu, Young Nam Kang, Ji Sun Jang, Si Hyun Bae, Seung Kew Yoon, Ihl Bohng Choi, Ki Mun Kang, Hong Seok Jang.   

Abstract

PURPOSE: To identify the parameters that predict hepatic toxicity and deterioration of hepatic function.
MATERIALS AND METHODS: A total of 47 patients with small unresectable primary hepatocellular carcinoma received hypofractionated stereotactic body radiotherapy (SBRT) using the CyberKnife. Of those, 36 patients received no other local treatments that could influence hepatic toxicity at least for 3 months after the completion of SBRT. The gross tumor volume (GTV) was 18.3 ± 15.9 cm(3) (range, 3.0-81.3 cm(3)), and the total dose administered was 30-39 Gy (median, 36 Gy). To assess the deterioration of hepatic function, we evaluated the presence or absence of the progression of Child-Pugh class (CP class). To identify the parameters of predicting the radiation-induced hepatic toxicity and deterioration of the hepatic function, several clinical and dose-volumetric parameters were evaluated.
RESULTS: Of 36 patients, 12 (33%) developed Grade 2 or higher hepatic toxicity and 4 (11%) developed progression of CP class. The multivariate analysis showed that the only significant parameter associated with the progression of CP class was the total liver volume receiving a dose less than 18 Gy (<18 Gy).
CONCLUSIONS: The progression of CP class after SBRT limits other additional local treatments and also reflects the deterioration of hepatic function. Therefore, it would be important to note that the presence or absence of the progression of CP class is a dose-limiting factor. The total liver volume receiving <18 Gy should be greater than 800 cm(3) to reduce the risk of the deterioration of hepatic function.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20207492     DOI: 10.1016/j.ijrobp.2009.09.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  49 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Jpn J Clin Oncol       Date:  2016-01-29       Impact factor: 3.019

3.  Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation.

Authors:  Jennifer Pursley; Issam El Naqa; Nina N Sanford; Bridget Noe; Jennifer Y Wo; Christine E Eyler; Matthew Hwang; Kristy K Brock; Beow Y Yeap; John A Wolfgang; Theodore S Hong; Clemens Grassberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-27       Impact factor: 7.038

Review 4.  Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions.

Authors:  Timothy A Lin; Jessica S Lin; Timothy Wagner; Ngoc Pham
Journal:  J Gastrointest Oncol       Date:  2018-10

5.  SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.

Authors:  Haoming Qiu; Michael J Moravan; Michael T Milano; Kenneth Y Usuki; Alan W Katz
Journal:  J Gastrointest Cancer       Date:  2018-12

6.  Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage.

Authors:  Hiroshi Doi; Norihisa Masai; Kenji Uemoto; Osamu Suzuki; Hiroya Shiomi; Daisaku Tatsumi; Ryoong-Jin Oh
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

7.  Locally ablative non-surgical management of colo-rectal liver metastasis.

Authors:  Amit Bahl; Rakesh Kapoor; Pramod Kumar Singh; Tapesh Bhattacharya; Oinam S Arun; Tomar Parsee; Suresh C Sharma
Journal:  J Gastrointest Cancer       Date:  2013-03

Review 8.  Radiotherapy for liver tumors.

Authors:  Florence K Keane; Shyam K Tanguturi; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Hepat Oncol       Date:  2015-04-20

Review 9.  Liver-Directed Radiotherapy for Hepatocellular Carcinoma.

Authors:  Florence K Keane; Jennifer Y Wo; Andrew X Zhu; Theodore S Hong
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

10.  Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study.

Authors:  Ashley A Weiner; Jeffrey Olsen; Daniel Ma; Pawel Dyk; Todd DeWees; Robert J Myerson; Parag Parikh
Journal:  Radiother Oncol       Date:  2016-08-23       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.